Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01192503 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Rasagiline in Restless Legs Syndrome
A Phase 2 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01192503 is a Phase 2 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 52 participants.
The verdict
NCT01192503, a Phase 2 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if rasagiline improves RLS symptoms. We also want to make sure rasagiline is safe to give people with RLS.
Interventions
- DRUG rasagiline
- DRUG placebo (sugar pill)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01192503
The ClinicalTrials.gov registry entry for NCT01192503 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rasagiline is the first listed.
NCT01192503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01192503 about?
NCT01192503 is a clinical study titled "Safety and Efficacy of Rasagiline in Restless Legs Syndrome". The purpose of this study is to find out if rasagiline improves RLS symptoms. We also want to make sure rasagiline is safe to give people with RLS.
What is the current status of trial NCT01192503?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-09. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01192503?
The interventions under investigation include: rasagiline (DRUG), placebo (sugar pill) (DRUG).
Who is sponsoring clinical trial NCT01192503?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.